Ultivue, a Cambridge, Mass.-based leader in tissue biomarker identification and quantification assays for translational and pathology research labs, closed a $22M Series C funding.
The round was led by new investor Northpond Ventures with participation from existing investors ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital, and Applied Ventures.
The company intends to use the funds to further extend its leadership position primarily through the expansion of its portfolio of UltiMapper™ kits with an increasing level of product customization, and accelerate its international market presence with increased investments in sales, field application scientists and marketing across all regions with an immediate focus on Asia.
Led by Michael Natan, CEO, Ultivue makes multiplexed biomarker assays in tissue for research in personalized medicine and digital pathology. By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), the company is connecting the insights gained from research directly into the pathology lab. Its UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution, while fitting completely within traditional IHC workflows.
Translational and clinical researchers usr the assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools.
Ultivue is expanding its UltiMapper™ assay product portfolio and menu of contract research services to provide a comprehensive set of personalized medicine solutions for oncology research as well as other therapeutic areas.